TY - JOUR
T1 - Epidemiology of vancomycin-resistant enterococci in Canadian hospitals (CANWARD study, 2007 to 2013)
AU - Simner, P. J.
AU - Adam, H.
AU - Baxter, M.
AU - McCracken, M.
AU - Golding, G.
AU - Karlowsky, J. A.
AU - Nichol, K.
AU - Lagacé-Wiens, P.
AU - Gilmour, M. W.
AU - Hoban, D. J.
AU - Zhanel, G. G.
AU - Canadian Antimicrobial Resistance Alliance (CARA)
N1 - Publisher Copyright:
© 2015, American Society for Microbiology. All rights reserved.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Of 1,927 Enterococcus species isolates collected across Canada from 2007 to 2013, 80 (4.2%) were identified as vancomycin-resistant enterococci (VRE). VRE infections during this time tripled in Canadian hospitals, from 1.8% to 6.0% (P = 0.03). All VRE were Enterococcus faecium, with 90% possessing vanA. The prevalence of vanB decreased from 37.5% in 2007 to 0% in 2013 (P < 0.05). The VRE were multidrug resistant, but 70.6%, 86.3%, and 100% were susceptible to doxycycline, linezolid, and daptomycin, respectively.
AB - Of 1,927 Enterococcus species isolates collected across Canada from 2007 to 2013, 80 (4.2%) were identified as vancomycin-resistant enterococci (VRE). VRE infections during this time tripled in Canadian hospitals, from 1.8% to 6.0% (P = 0.03). All VRE were Enterococcus faecium, with 90% possessing vanA. The prevalence of vanB decreased from 37.5% in 2007 to 0% in 2013 (P < 0.05). The VRE were multidrug resistant, but 70.6%, 86.3%, and 100% were susceptible to doxycycline, linezolid, and daptomycin, respectively.
UR - http://www.scopus.com/inward/record.url?scp=84931292097&partnerID=8YFLogxK
U2 - 10.1128/AAC.00384-15
DO - 10.1128/AAC.00384-15
M3 - Article
C2 - 25896693
AN - SCOPUS:84931292097
VL - 59
SP - 4315
EP - 4317
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
SN - 0066-4804
IS - 7
ER -
